Chagas Disease: “The New HIV/AIDS of the Americas” by Hotez, Peter J. et al.
Editorial
Chagas Disease: ‘‘The New HIV/AIDS of the Americas’’
Peter J. Hotez
1,2*, Eric Dumonteil
3, Laila Woc-Colburn
2,4, Jose A. Serpa
2,4, Sarah Bezek
2,5,
Morven S. Edwards
2,6, Camden J. Hallmark
2,7, Laura W. Musselwhite
8, Benjamin J. Flink
8,
Maria Elena Bottazzi
1,2
1Departments of Pediatrics and Molecular Virology & Microbiology, and Sabin Vaccine Institute and Texas Children’s Center for Vaccine Development, Baylor College of
Medicine, Houston, Texas, United States of America, 2National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America,
3Laboratorio de Parasitologia, Centro de Investigaciones Regionales ‘‘Dr Hideyo Noguchi’’, Universidad Autonoma de Yucatan, Merida, Yucatan, Mexico, 4Section of
Infectious Diseases, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, United States of America, 5Department of Emergency Medicine, Baylor
College of Medicine, Houston, Texas, United States of America, 6Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas,
United States of America, 7Houston Department of Health and Human Services, Houston, Texas, United States of America, 8Duke University School of Medicine, Durham,
North Carolina, United States of America
Endemic Chagas disease has emerged as an
important health disparity in the Americas. As a
result, we face a situation in both Latin America
and the US that bears a resemblance to the early
years of the HIV/AIDS pandemic.
Neglected tropical diseases (NTDs) are
among the most common conditions
afflicting the estimated 99 million people
who live on less than US$2 per day in the
Latin American and Caribbean (LAC)
region [1]. Almost all of the ‘‘bottom 100
million’’ living in the Americas suffer from
at least one NTD [1], and according to
some estimates, the NTDs cause a burden
of disease in the LAC region that closely
approximates or even exceeds that result-
ing from HIV/AIDS [2]. Chagas disease
(American trypanosomiasis) is a vector-
borne disease and a leading cause of the
deaths and disability-adjusted life years
(DALYs) lost that result from NTDs in the
LAC region [2]. With approximately 10
million people living with Chagas disease,
this condition is one of the most common
NTDs affecting the bottom 100 million in
the region, a prevalence exceeded only by
hookworm and other soil-transmitted hel-
minth infections [1,2]. Moreover, among
the NTDs in the Americas, Chagas disease
ranks near the top in terms of annual
deaths and DALYs lost [1,2].
While most of the world’s cases of
Chagas disease occur in the LAC region,
there is increasing recognition that many
people with Trypanosoma cruzi infection also
live in the US and Europe [3]. In practical
terms, the ‘‘globalization’’ of Chagas
translates to up to 1 million cases in the
US alone, with an especially high burden
of disease in Texas and along the Gulf
coast [4,5], although other estimates
suggest that there are approximately
300,000 cases in the US [6], in addition
to thousands of cases documented in
Canada, Europe, Australia, and Japan
[3]. Among those living with Chagas
disease around the world today, 20%–
30% (roughly 2–3 million people) are
either currently suffering from Chagasic
cardiomyopathy or will develop this clin-
ical sequela [7]. Chagasic cardiomyopathy
is a highly debilitating condition charac-
terized by cardiac arrhythmias, heart
failure, and risk of sudden death from
ventricular fibrillation or tachycardia or
thromboembolic events [7]. Another esti-
mate suggests that up to 5.4 million people
living today will develop Chagasic cardio-
myopathy [8,9]. Damage to the gastroin-
testinal tract can also produce debilitating
megaesophagus and megacolon [7].
There are a number of striking similar-
ities between people living with Chagas
disease and people living with HIV/AIDS,
particularly for those with HIV/AIDS
who contracted the disease in the first
two decades of the HIV/AIDS epidemic.
Both diseases are health disparities, dis-
proportionately affecting people living in
poverty [1,2]. Both are chronic conditions
requiring prolonged treatment courses: a
lifetime of antiretroviral therapy for HIV/
AIDS patients, and one to three months of
therapy for those with Chagas disease [7].
Treatment for HIV/AIDS is lifesaving,
although it seldom if ever results in cure,
while for Chagas disease, the treatment
has proven efficacy only for the acute
stages of the infection or in children up to
12 years of age during the early chronic
phase of the infection [10]. For both
diseases the treatment is expensive—in
the case of Chagas disease, the expected
cost of treatment per patient year is
$1,028, with lifetime costs averaging
$11,619 per patient [11]. Exacerbating
costs, Chagas disease itself is a serious
opportunistic infection of people living
with HIV/AIDS, and is associated with
meningoencephalitis, cerebral lesions, and
high mortality [7]. As with patients in the
first two decades of the HIV/AIDS
epidemic, most patients with Chagas
disease do not have access to health care
facilities. A recent analysis indicates that
many patients do not have access to the
essential medicines for Chagas disease, in
particular, the first line of therapy, the
drug benznidazole [12]. According to
Me ´decins Sans Frontie `res (MSF, Doctors
Without Borders), many highly endemic
countries, including Paraguay and Bolivia,
face acute shortages of benznidazole,
forcing thousands of newly diagnosed
patients to postpone treatment [12]. Both
diseases are also highly stigmatizing, a
feature that for Chagas disease further
complicates access to benznidazole and
other essential medicines, as well as access
to serodiagnosis and medical counseling.
For some individuals with T. cruzi living in
the US, immigration status presents an
additional challenge to seeking care and
prevention services. Just as stigma due to
sexual orientation has been a barrier to
HIV care and prevention, especially in the
beginning of the epidemic, immigration
status may function as a deterrent to
Chagas disease care and prevention.
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above—the chronic morbidities and high
mortalities, the prolonged and expensive
treatment courses, the lack of therapeutic
options, and barriers to access to essential
medicines—a patient living with Chagas
disease faces formidable challenges that
resemble those faced by someone living
with HIV/AIDS, especially the challenges
that occurred in the early years of the
HIV/AIDS epidemic. Shown in Table 1 is
a quantitative comparison between people
living with Chagas disease [2,4,6,13,14]
and those living with HIV/AIDS in the
LAC region and the Americas [13–17].
Briefly, the roughly 10 million people
living with Chagas disease (including 2–5
million individuals with Chagasic cardio-
myopathy) is comparable in number to the
1.6 million people living with HIV/AIDS
in the LAC region and the 1–2 million
living with HIV/AIDS in North America
(including Mexico). However, based on
current estimates, both the number of
annual DALYs lost and the attributed
deaths are about five times higher for
HIV/AIDS. The morbidity and mortality
estimates for both Chagas disease and
HIV/AIDS are undergoing revision by
the University of Washington Institute of
Health Metrics and Evaluation.
There are additional parallels. Chagas
disease has emerged as an important blood
transfusion–related risk throughout the
Americas just as HIV/AIDS did in the
early 1980s, prior to the implementation
of widespread blood screening and testing
[18–20]. Moreover, mother-to-child trans-
mission leading to congenital Chagas
disease and other adverse neonatal out-
comes is increasingly recognized [21–24]
(Table 2). Both congenital Chagas disease
and HIV/AIDS have a recognized clinical
syndrome [21,25], with adverse birth
outcomes as well as deleterious maternal
effects in pregnancy [22,23,26]. During
pregnancy, the rate of vertical transmis-
sion of T. cruzi infection is approximately
5% (although some investigators believe
the rate could be as high as 10%), whereas
it is 15%–40% for untreated HIV/AIDS
[27] and 1%–2% for mothers who receive
antiretroviral therapy [28]. The Pan
American Health Organization estimates
that there are over 14,000 cases of
congenital Chagas disease in Latin Amer-
ica [29], with 2,000 newborns infected
annually in North America alone [24],
compared to 36,000 pediatric HIV/AIDS
cases in Latin America [15].
It is only appropriate to point out that
there are important differences between
Chagas disease and HIV/AIDS. Whereas
HIV/AIDS is almost always a fatal
condition in the absence of antiviral
therapy, up to 70%–80% of people with
Chagas disease do not progress to cardio-
myopathy. Moreover, Chagas disease is a
true NTD and there is a paucity of anti-
protozoan drugs available for this condi-
tion, whereas HIV/AIDS can no longer
be considered neglected in this sense as
there is an armamentarium of antiretrovi-
ral drugs currently available (although for
both conditions, patients in developing
countries suffer from lack of access to
essential medicines). As another contrast
between the two diseases, there is also
evidence for oral transmission of Chagas
through food contamination in the Ama-
zon basin [30].
Over the last three decades of the global
HIV/AIDS pandemic, an aggressive and
committed activist community has
achieved success in promoting widespread
access to antiretroviral drugs in developed
and developing countries. As a result, at
present millions of people living with
HIV/AIDS receive antiretroviral therapy,
and pediatric HIV/AIDS has been nearly
eliminated as a public health problem in
the US [31]. Patient advocacy and global
efforts to promote access to benznidazole
and other therapies for Chagas disease, on
the other hand, are at a much earlier
stage. In the last decade, MSF has
launched efforts to screen more than
80,000 people in Bolivia, Colombia,
Guatemala, Honduras, Nicaragua, and
Paraguay, having diagnosed and treated
more than 6,000 and 4,000 individuals,
respectively [12]. Other non-governmen-
tal organizations have also been engaged
in Chagas disease treatments. Of great
concern is a looming shortage of benzni-
dazole, as well as the over-reliance on a
single drug manufacturer, and inadequate
international efforts to organize global
production and distribution of the drug
in Latin America [12]. Nifurtimox, anoth-
er drug commonly used in the treatment of
Chagas disease, should also be made
available for the LAC region.
In parallel with global advocacy efforts,
expansion of operational research activi-
ties is crucial to optimize the efficacy of
existing control and elimination efforts,
including the testing of more field-adapted
tools [12]. There are also requirements to
expand vector control activities and health
education in the communities affected by
Chagas disease, in addition to providing
training for local health care providers in
endemic areas [12]. The importance of a
research and development agenda to
develop new and improved Chagas disease
drugs cannot be overlooked. As noted
above, both antitrypanosomal drugs used
for the treatment of Chagas disease,
benznidazole and nifurtimox, require pro-
longed and expensive treatment courses;
moreover, the efficacy of either drug for
the treatment of late chronic infection and
Chagasic cardiomyopathy still remains
uncertain and unproven [32,33]. Toxici-
ties and the frequency of side effects of
both medicines frequently require patients
to interrupt or halt treatments, and both
drugs are contraindicated in pregnancy
[34–36]. In response to this crisis, the
product development partnership (PDP)
Drugs for Neglected Diseases initiative
(DNDi) is accelerating the development
of new Chagas disease drugs in the non-
profit sector, in parallel with a small group
of academic laboratories that are pursuing
several drug targets [37,38]. Finally, just as
Table 1. Comparison of Chagas disease versus HIV/AIDS.
Disease
Estimated Number of Cases
in LAC [Reference]
Estimated Number
of Cases in North
America [Reference]
Estimated DALYs
in the Americas
[Reference]
Estimated Annual
Deaths in the
Americas [Reference]
Countries Most
Affected [Reference]
Chagas disease 8–9 million (2–5 million cases of
Chagasic cardiomyopathy) [2]
0.3–1.0 million in
the US [4,6]
0.7 million [13] 14,000 [14] Bolivia, Mexico, Colombia,
Central America [2]
HIV/AIDS 1.6 million [15,16] 2.3 million
a [17] 3.2 million [13] 105,000
a [15–17] Brazil, Mexico, Colombia,
United States [15–17]
aThe UNAIDS data for North America also includes Western and Central Europe. According to the US Centers for Disease Control and Prevention, at the end of 2008 an
estimated 1.2 million people were living with HIV in the US [40].
doi:10.1371/journal.pntd.0001498.t001
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(IAVI) PDP is developing several experi-
mental HIV/AIDS vaccines, the Sabin
Vaccine Institute PDP is accelerating the
development of a new therapeutic Chagas
disease vaccine in collaboration with
several key universities and public sector
biotechnology and manufacturing institu-
tions in Mexico [1]. In further support of
this research, a recent analysis by Lee and
his colleagues confirms the potential cost
effectiveness of Chagas disease vaccines
[39].
Stark similarities exist between today’s
global Chagas disease epidemic and the
first two decades of the HIV/AIDS
epidemic. This translates into a humani-
tarian catastrophe for the poorest people
in the Americas and elsewhere. This
perceptible health disparity demands ur-
gent attention by global health policy
makers to prioritize Chagas disease and
develop a comprehensive strategy for
control and elimination efforts, blood
screening and point-of-care testing, mater-
nal and child interventions, health educa-
tion, and parallel research and develop-
ment. Successfully addressing the vast
burden of Chagas disease will require
overcoming the current lack of available
drugs, together with expanding vector
control strategies and developing new
and innovative control tools. To this end,
eliminating Chagas disease will require a
commitment from international health
agencies, governments of the disease-
endemic countries, PDPs, and patient
advocacy groups.
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